Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2001

View Archived Issues

Dose-response study completed for Corvas's thrombosis prophylactic rNAPc2

PhotoCure applies for approval of photodynamic skin cancer therapy throughout Europe

NCI awards Phase I SBIR grant to Kosan Biosciences for anticancer compound

FDA places TP-10 pediatric trials on hold

Novel benzothiophene HSV-1 inhibitor identified by Pfizer

YM-471 shows potent affinity and selectivity for human vasopressin V1A and V2 receptors

Chronic dronedarone differs strongly from chronic amiodarone in the canine heart

Shire's once-daily treatment for ADHD receives FDA approvable letter

Cell Pathways begins phase II trials of CP-461 in several types of cancer

Vion initiates phase II clinical trials of Triapine for metastatic breast cancer

FDA approves new seven-day treatment for community-acquired pneumonia

Novel caspase inhibitors patented by Vertex

Lilly identifies compounds useful for potentiating glutamate receptor function

Benzyl tetralins reported to have potential in treating androgen- or estrogen-mediated diseases

Oxadiazolin-2-ones with elastase inhibitory activity reported by Ono Pharmaceuticals

Merck & Co. presents new cytokine inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...